Bristol Myers Squibb (BMS) is strategically positioning itself for sustained growth through the 2030s, with upcoming pivotal Phase III readouts for its promising pipeline candidates, milvexian and Cobenfy, at the forefront of its agenda. This forward-looking strategy aims to counterbalance the impending patent expirations of key revenue drivers, most notably the blockbuster anticoagulant Eliquis. The company’s confidence in these next-generation therapies was underscored during its first-quarter earnings call, where management highlighted the "blockbuster potential" of these drugs as crucial for maintaining its market leadership.
The pharmaceutical giant, headquartered in New Jersey, reported modest financial results for the first quarter of 2026, with total revenues inching up 1% year-over-year to $11.5 billion, a figure that slightly surpassed analyst consensus. When adjusted for currency fluctuations, the growth remained steady. Non-GAAP earnings per share (EPS) also exceeded expectations, reaching $1.58, compared to the $1.46 forecast by William Blair analysts. This steady performance was partly buoyed by a 9% year-over-year increase in revenue from BMS’s "growth portfolio," which generated $6.2 billion. Among the standout performers within this segment was Camzyos (mavacamten), a therapy for obstructive hypertrophic cardiomyopathy, which saw a remarkable 97% surge in revenue, contributing $314 million in the first quarter. Despite these moderate gains, BMS reaffirmed its 2026 revenue guidance, projecting a total between $46 billion and $47.5 billion, signaling a commitment to its long-term financial objectives.
Milvexian: The Potential Successor to Eliquis
A significant focus of BMS’s growth strategy revolves around milvexian, a Factor XIa (FXIa) inhibitor poised to become the next-generation anticoagulant and a potential successor to the highly successful Eliquis. Eliquis, developed in partnership with Pfizer, has been a cornerstone of BMS’s revenue, generating $4.1 billion in global revenue in the first quarter alone, a substantial 16% increase compared to the same period in 2025. However, with Eliquis’s patent protection anticipated to expire in 2027, the company faces a critical need to fill this impending revenue gap.
Milvexian is currently undergoing rigorous evaluation in two pivotal Phase III clinical trials. The first, identified by clinical trial number NCT05757869, is investigating its efficacy in patients with atrial fibrillation. The second, NCT05702034, is assessing its role in secondary stroke prevention. Readouts from both of these crucial trials are anticipated within the current year. During the earnings call, Adam Lenkowsky, Executive Vice President and Chief Commercialization Officer at BMS, expressed strong optimism about milvexian’s prospects, stating its "true blockbuster potential." He elaborated that this potential hinges on the drug demonstrating a superior bleeding profile and enhanced efficacy when directly compared to Eliquis.
The path for milvexian has not been without its challenges. In November 2025, BMS and its co-developer, Johnson & Johnson (J&J), made the decision to terminate a late-stage trial evaluating milvexian in acute coronary syndrome (ACS). This decision was attributed to a low probability of the drug meeting its primary endpoint. At the time of the termination, analysts expressed concerns that this outcome might cast a shadow of doubt over the ongoing stroke study, suggesting a potential for negative read-through. Despite this setback, the company continues to invest heavily in milvexian, underscoring its strategic importance in the anticoagulant market.
Cobenfy: Expanding Horizons in Schizophrenia and Beyond
Another key asset in BMS’s pipeline with significant growth potential is Cobenfy (xanomeline/trospium chloride), a therapy for schizophrenia. Upon its approval in 2024, BMS heralded Cobenfy as a critical growth driver capable of mitigating the impact of patent expiries. In the first quarter of 2026, Cobenfy demonstrated a robust 107% increase in global revenue, reaching $56 million, a performance that met analyst consensus. However, the drug’s market adoption has been described as "slow," with contributing factors including physician hesitancy in prescribing the medication and challenges related to patient access through insurance coverage in the United States.
Despite a somewhat subdued initial market entry, BMS sees substantial opportunities for Cobenfy to achieve greater commercial success. The company is actively pursuing several new indications for the drug, with upcoming clinical readouts expected to provide critical data. A significant development will be the release of data from the ADEPT program, a pivotal three-trial initiative investigating Cobenfy in Alzheimer’s disease psychosis. These results are anticipated by late 2026. Furthermore, BMS is exploring Cobenfy’s potential in other neurological and psychiatric conditions, including bipolar I disorder, agitation associated with Alzheimer’s disease, and cognitive impairment in Alzheimer’s disease. Clinical readouts for these expanded indications are projected to occur between 2026 and 2029.
The market outlook for Cobenfy is optimistic, with Citi analysts forecasting that the drug could achieve sales of $2.2 billion by 2030. This projection highlights the perceived significant unmet need and the potential for Cobenfy to capture a substantial market share across its intended indications.
Pumitamig and the Broader Pipeline
Beyond milvexian and Cobenfy, BMS also has its sights set on pumitamig, a bispecific antibody targeting PD-1 and VEGF. While details regarding pumitamig’s development stage and specific readouts were not as prominently featured in the Q1 earnings call, its inclusion in the list of potential growth drivers indicates its strategic importance. Bispecific antibodies are a rapidly advancing area of oncology, offering the potential for novel therapeutic mechanisms and improved patient outcomes. The company’s investment in such innovative modalities underscores its commitment to maintaining a competitive edge in the oncology landscape.
Financial Performance and Future Outlook
The first quarter of 2026 presented a mixed financial picture for BMS. While total revenue growth was modest, the performance of its growth portfolio, particularly Camzyos, provided a positive indicator of the company’s ability to nurture and expand its newer assets. The reaffirmation of the 2026 revenue guidance suggests management’s confidence in the company’s ability to navigate the challenges of patent expirations and capitalize on the potential of its late-stage pipeline.
The upcoming Phase III readouts for milvexian and Cobenfy are undoubtedly critical inflection points for BMS. The success of milvexian in demonstrating superior safety and efficacy profiles compared to Eliquis could solidify its position as the leading anticoagulant for years to come, effectively securing the future of this crucial therapeutic area. For Cobenfy, positive data from the ADEPT program and subsequent indications could transform it from a niche schizophrenia treatment into a multi-indication blockbuster, significantly bolstering BMS’s neuroscience portfolio.
The company’s strategic emphasis on these two key assets, alongside its continued investment in innovative oncology treatments, reflects a calculated approach to long-term value creation. Investors will be closely watching the progress of these clinical trials, as their outcomes will have a profound impact on BMS’s market position, revenue streams, and its ability to thrive through the coming decade and beyond. The pharmaceutical industry is characterized by intense competition and rapid scientific advancement, and BMS’s proactive strategy to cultivate and advance its pipeline is a testament to its ambition to remain a leader in delivering life-changing medicines. The coming years, marked by crucial data releases, will be pivotal in determining whether BMS can successfully transition from its current revenue drivers to a new era of growth powered by milvexian, Cobenfy, and other promising pipeline assets.
Leave a Reply